Literature DB >> 12460055

Fanconi syndrome and renal failure induced by tenofovir: a first case report.

David Verhelst1, Matthieu Monge, Jean-Luc Meynard, Bruno Fouqueray, Béatrice Mougenot, Pierre-Marie Girard, Pierre Ronco, Jerome Rossert.   

Abstract

Although nephrotoxicity of cidofovir and adefovir is well established, no renal side effects have been observed yet with tenofovir, which is the third member of this family. The authors report the case of a patient who had Fanconi syndrome, nephrogenic diabetes insipidus, and acute renal failure during treatment with tenofovir, a nucleotide reverse transcriptase inhibitor that recently has been approved by the Food and Drug Administration for treatment of patients infected with human immunodeficiency virus. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460055     DOI: 10.1053/ajkd.2002.36924

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  76 in total

Review 1.  Hepatitis B therapy.

Authors:  Hellan Kwon; Anna S Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

2.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

3.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.

Authors:  Yun Bin Lee; Jeong-Hoon Lee; Dong Hyeon Lee; Hyeki Cho; Hongkeun Ahn; Won-Mook Choi; Young Youn Cho; Minjong Lee; Jeong-Ju Yoo; Yuri Cho; Eun Ju Cho; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Chung Yong Kim; Hyo-Suk Lee
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 5.  Disease management--constructing optimal NRTI-based combinations: past, present, and future.

Authors:  Douglas T Dieterich
Journal:  MedGenMed       Date:  2006-01-19

6.  Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.

Authors:  E T Overton; D Nurutdinova; J Freeman; W Seyfried; K E Mondy
Journal:  HIV Med       Date:  2009-03-11       Impact factor: 3.180

7.  A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.

Authors:  Amber Dahlin; Matthias Wittwer; Melanie de la Cruz; Jonathan M Woo; Rujuta Bam; Valeska Scharen-Guivel; John Flaherty; Adrian S Ray; Tomas Cihlar; Samir K Gupta; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

Review 8.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Bilateral sub-trochanteric femur fragility fractures in a patient on antiretroviral therapy: a case based discussion and review of literature.

Authors:  Rajesh K Rajnish; Pratik M Rathod; Sameer Aggarwal; Saurabh Agarwal; Prasoon Kumar
Journal:  Int J Burns Trauma       Date:  2020-08-15

10.  Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report.

Authors:  Antonio Di Biagio; Raffaella Rosso; Patrizia Monteforte; Rodolfo Russo; Guido Rovetta; Claudio Viscoli
Journal:  J Med Case Rep       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.